BIND, Amgen collaborate on solid tumor drug development

01/9/2013 | American City Business Journals

Amgen and BIND Biosciences agreed to develop a drug for solid tumors using the latter's technology platform. The partners hope to develop a new class of drug that would be more effective and less toxic than existing chemotherapy treatments. BIND could potentially receive up to $180.5 million in upfront and milestone fees, plus royalties.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT